Janus Henderson Group PLC Sells 84,661 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Janus Henderson Group PLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 86.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 13,473 shares of the biopharmaceutical company’s stock after selling 84,661 shares during the period. Janus Henderson Group PLC’s holdings in Regeneron Pharmaceuticals were worth $9,599,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. OFI Invest Asset Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $28,000. Rakuten Securities Inc. boosted its position in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares in the last quarter. Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Crowley Wealth Management Inc. bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Finally, Private Wealth Management Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Bank of America cut their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating on the stock in a research report on Thursday, April 17th. Piper Sandler dropped their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 5th. Royal Bank of Canada dropped their price target on Regeneron Pharmaceuticals from $1,051.00 to $943.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 30th. Finally, TD Cowen lowered their price objective on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th. One analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $890.60.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $594.32 on Friday. Regeneron Pharmaceuticals, Inc. has a one year low of $520.50 and a one year high of $1,211.20. The business has a fifty day moving average price of $599.96 and a 200-day moving average price of $684.64. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The firm has a market capitalization of $64.17 billion, a P/E ratio of 15.53, a PEG ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to the consensus estimate of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue was down 3.7% on a year-over-year basis. During the same period in the previous year, the business earned $9.55 earnings per share. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.59%. The ex-dividend date is Tuesday, May 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.96%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.